Dendreon Reports Q2 Earnings On July 30 Seeking Alpha ... Spectrum Pharmaceuticals Inc announced the initiation of a Phase II study evaluating ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use + rituximab in combination with motexafin gadolinium (MGd) in patients with rituximab-refractory low ... |
